Project Grant R21AI185435
Award Date
7/18/25
Completion Date
6/30/27
Dollars Obligated
$401K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Reno, NV 89557, USA
Similar Awards
This $505,238 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to identify skin-associated compounds that can disrupt mosquito landing and biting behavior. The overarching goal is to discover new chemical compounds that can act as improved topical insect repellents compared to DEET, especially for use in tropical regions. The research will involve validating...
This federal Project Grant award of $429,000.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to examine chromatin architecture and gene regulatory networks in Anopheles coluzzii mosquito hemocyte cells. The key objectives are to 1) map chromatin architecture during immune activation in mosquito hemocyte cells, and 2) identify gene regulatory networks for the immune...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $103,256 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Medical College of Wisconsin, Inc. The grant, entitled "Effects of a Chromosomal Inversion on Gene Regulation in a Major Malaria Vector", aims to study the mechanisms by which a chromosomal inversion in Anopheles coluzzii mosquitoes confers resistance to malaria infection. The research will biochemically and...
This $588,514 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop new tools for improving mosquito population suppression technologies in Aedes aegypti, a key disease vector. The key focus areas include: Evaluating conditional and sex-specific lethal systems that can restrict lethal transgene expression to reduce fitness load on the mosquito population. This includes...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $218,900 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Alabama at Birmingham (UAB) to investigate the molecular determinants that influence flavivirus protease cleavage and how these factors affect viral fitness. The project aims to elucidate the proteolytic mechanisms used by flaviviruses, such as Dengue, Zika, West Nile, and Yellow Fever viruses, to...
The federal Project Grant award R21AI188026 in the amount of $423,125.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development of an intein-based QF2 system for controllable protein expression in the nervous system of the Aedes aegypti mosquito. This research aims to disrupt the propagation of mosquito-transmitted viruses such as dengue, Zika, yellow fever, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $648,924 to Iowa State University of Science and Technology to conduct research on the role of mosquito extracellular vesicles in malaria parasite killing and immune priming. The project aims to obtain a mechanistic understanding of how these extracellular vesicles function within the mosquito immune system...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,248,576 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The grant, awarded on July 25, 2025, will fund research to understand the cross-protective efficacy of the recently FDA-approved IXCHIQ live attenuated chikungunya virus vaccine against other alphavirus species, assess the vaccine's infectivity and transmissibility in mosquitoes, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $441,502 to the University of Texas Health Science Center at Houston (UTHealth) to advance CRISPR-based genome editing strategies for managing Aedes aegypti mosquito populations. The key objectives are to: 1) design a CAS12 temperature-dependent system that requires only one strain to produce sterile male...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $790,000.00 in funding to the Regents of the University of Minnesota to conduct research on the immune response to West Nile virus (WNV) and the factors that influence the development of neuroinvasive disease. The goal is to gain a molecular understanding of WNV neuroinvasion, central nervous system immunity, and the...